Miltefosine

Catalog No.S3056 Synonyms: Hexadecylphosphocholine

Miltefosine Chemical Structure

Molecular Weight(MW): 407.57

Miltefosine inhibits PI3K/Akt activity with ED50 of 17.2 μM and 8.1 μM in carcinoma cell lines A431 and HeLa, first oral drug for Visceral leishmaniasis, effective against both promastigotes and amastigotes.

Size Price Stock Quantity  
USD 70 In stock
USD 90 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Effects of a miltefosine co-treatment with celecoxib on steatohepatitis, hepatocyte apoptosis, Akt activation and p53 expression in the liver of MCD-diet fed mice. Mice were fed the control diet, an MCD diet, an MCD diet with celecoxib (20 mg/kg/day) treatment, or an MCD diet co-treatment with celecoxib and miltefosine (50 mg/kg/day) for 3 weeks. (C) TUNEL-stained sections of liver samples are representative of the indicated groups (magnification×400). Abbreviations: MCD, methionine and choline deficient; CON, control; CEL, celecoxib; MTF, miltefosine.

    Biochem Biophys Res Commun, 2016, 469(4):1034-40.. Miltefosine purchased from Selleck.

    Effects of a miltefosine co-treatment with celecoxib on steatohepatitis, hepatocyte apoptosis, Akt activation and p53 expression in the liver of MCD-diet fed mice. Mice were fed the control diet, an MCD diet, an MCD diet with celecoxib (20 mg/kg/day) treatment, or an MCD diet co-treatment with celecoxib and miltefosine (50 mg/kg/day) for 3 weeks. (A) HE-stained and oil red O-stained sections of liver samples are representative of the indicated groups. (Original magnification×200) (B) Hepatic triglyceride levels in the indicated groups. (C) TUNEL-stained sections of liver samples are representative of the indicated groups (magnification×400). (D) Hepatic apoptotic index in the indicated groups. (E) Serum ALT levels in the indicated groups. (F) phosphorylated Akt and p53 protein levels were determined by Western blotting in mice fed the control diet, MCD, MCD with celecoxib (20 mg/kg/day) treatment, or an MCD diet and treatment with celecoxib and miltefosine (50 mg/kg/day) for 3 weeks. (G and H) Bands were quantified, Graphs represent the gray value ratio of phosphorylated Akt to total Akt and p53 protein to GAPDH. Data are expressed as the means ± SME (n = 4−6 mice/group). *P < 0.05, compared with control group; #P < 0.05 compared with MCD mice; **P < 0.05, compared with MCD + CEL group. Abbreviations: MCD, methionine and choline deficient; CON, control; CEL, celecoxib; MTF, miltefosine.

    Biochem Biophys Res Commun, 2016, 469(4):1034-40. . Miltefosine purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description Miltefosine inhibits PI3K/Akt activity with ED50 of 17.2 μM and 8.1 μM in carcinoma cell lines A431 and HeLa, first oral drug for Visceral leishmaniasis, effective against both promastigotes and amastigotes.
Targets
Akt [2] PI3K [2] PKC [1]
~7 μM
In vitro

Miltefosine is an alkylphosphocholine drug with demonstrated activity against various parasite species and cancer cells as well as some pathogenic bacteria and fungi. Miltefosine inhibits PKC from NIH3T3 cells in cell-free extracts with a IC50 of about 7 μM.[1] Miltefosine targets HIV infected macrophages, which play a role in vivo as long-lived HIV-1 reservoirs. Miltefosine acts by inhibiting the PI3K/Akt pathway, thus removing the infected macrophages from circulation, without affecting healthy cells.[2] Miltefosine inhibits the PI3K/Akt survival pathway in carcinoma cell lines.[3] Miltefosine causes skeletal muscle insulin resistance in vitro by interfering with the insulinsignalling pathway and inhibiting insulin-stimulated glucose uptake. Miltefosine inhibits insulin-stimulated Akt phosphorylation in a dose-dependent manner with 75% inhibition at 40 μM and 98% inhibition at 60 μM.[4]

In vivo Miltefosine inhibits anti-IgE induced histamine release from human skin mast cells. Miltefosine can reduce cytokines IL-1β, IL-4, and IL-6 in certain skin tissue cells and also strongly impede the esterification of cholesterol. [5]

Protocol

Cell Research:[6]
+ Expand
  • Cell lines: BCLM, VG-1, BC-1, and BCBL-1 PEL cell lines
  • Concentrations: 10, 20, 30, 40, and 50μM
  • Incubation Time: 3 days
  • Method: 2 × 105 PEL cells are treated with the therapeutic compounds at the indicated doses or with appropriate vehicle as a negative control. Cells are followed for 96 hours, and cell viability is determined by trypan blue exclusion performed in quadruplicate.
    (Only for Reference)
Animal Research: [6]
+ Expand
  • Animal Models: BC-1 cells xenografted NOD-SCID mice
  • Formulation: PBS
  • Dosages: 50 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro Water 81 mg/mL (198.73 mM)
Ethanol 81 mg/mL (198.73 mM)
DMSO Insoluble
In vivo Add solvents individually and in order:
Saline
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 407.57
Formula

C21H46NO4P

CAS No. 58066-85-6
Storage powder
Synonyms Hexadecylphosphocholine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03023111 Not yet recruiting Cutaneous Leishmaniasis Hospital Universitário Professor Edgard Santos|Oswaldo Cruz Foundation March 2017 Phase 3
NCT02687971 Not yet recruiting Cutaneous Leishmaniasis Drugs for Neglected Diseases August 2016 Phase 2
NCT02530697 Recruiting Leishmaniasis University of Brasilia August 2015 Phase 2
NCT02427308 Not yet recruiting Leishmaniasis or Other Uses of Miltefosine Knight Therapeutics (USA) Inc July 2015 --
NCT02429518 Not yet recruiting Mucocutaneous Leishmaniasis Knight Therapeutics (USA) Inc July 2015 --
NCT02431429 Not yet recruiting Mucocutaneous Leishmaniasis Knight Therapeutics (USA) Inc July 2015 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

Akt Signaling Pathway Map

Related Akt Products

Tags: buy Miltefosine | Miltefosine supplier | purchase Miltefosine | Miltefosine cost | Miltefosine manufacturer | order Miltefosine | Miltefosine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID